Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension
Jennifer A. Zimmer, John R. Sims, Cynthia Duggan Evans, Emel Serap Monkul Nery, Hong Wang, Alette M. Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Rakêt, Scott W. Andersen, Christophe Sapin, Marie-Ange Paget, Ivelina Gueorguieva, Paul A. Ardayfio, Rashna Khanna, Dawn A. Brooks, Brandy R. Matthews, Mark A. Mintun
- ISSN / E-ISSN
- — / —
- DOI
- 10.1016/j.tjpad.2025.100446 ↗
- Volume · Issue · Pages
- 13 · 2 · 100446-100446
- Publisher
- Springer International Publishing AG
- Article URL
- https://doi.org/10.1016/j.tjpad.2025.100446 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
01 Dec 2025
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 01 Dec 2025 | OpenAlex |
Keywords (as given): donanemab; long-term extension study; anti-amyloid therapy; amyloid PET; centiloid; disease progression; drug safety
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
Best available information, not a definitive status: Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
- Journal
- journal of prevention of Alzheimer's disease, The
- Publication date used
- 01 Dec 2025 (OpenAlex publication date)
- Applicable HEC period
- 2024–25 (version 1) · 01 Oct 2024 – 31 Mar 2026
- Category
- —
- Recognition status
- Pending Verification (PERIOD_HAS_UNMATCHED_ROWS)
- Source
- —
- Verification status
- Unverified
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.